WS
GNMX

Wedbush Securities’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Wedbush Securities’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-201,774
Closed -$141K – 969
2018
Q4 		$141K Hold
201,774
– – 0.02% 728
2018
Q3 		$248K Sell
201,774
-7,750
-4% -$8.66K 0.03% 678
2018
Q2 		$233K Buy
+209,524
New +$318K 0.03% 670

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wedbush Securities's GNMX Position: Q1 2019 in Review

Wedbush Securities sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 201,774 shares — an estimated $141K sold.

Wedbush Securities first reported a position in GNMX in Q2 2018 and held it in 3 quarters. The position peaked at $248K in Q3 2018. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

  • Wedbush Securities reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
  • Wedbush Securities sold 201,774 Aevi Genomic Medicine Inc shares in Q1 2019, an estimated $141K.
  • Wedbush Securities first reported a position in Aevi Genomic Medicine Inc in Q2 2018 and held it in 3 quarters.
  • Wedbush Securities's Aevi Genomic Medicine Inc position peaked at $248K in Q3 2018.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Wedbush Securities's 13F filing for Q1 2019, filed 17 Apr 2019.